CD274 and neoplasm: Among patients with tumor cell PD‐L1 expression <1%, the median OS was 12.0 months (95% CI 9.8–15.2) with nivolumab plus chemotherapy, 11.9 months (95% CI 10.1–16.0) with nivolumab plus ipilimumab, and 12.2 months (95% CI 10.7–14.0) with chemotherapy (Table S2).